Asset Details
Do you wish to reserve the book?
Identification of candidate cardiomyopathy modifier genes through genome sequencing and RNA profiling
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Identification of candidate cardiomyopathy modifier genes through genome sequencing and RNA profiling
Do you wish to request the book?
Identification of candidate cardiomyopathy modifier genes through genome sequencing and RNA profiling
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Identification of candidate cardiomyopathy modifier genes through genome sequencing and RNA profiling
2025
Overview
Phenotypic heterogeneity is apparent among individuals with putative monogenic disease, such as familial hypertrophic cardiomyopathy. Genome sequencing (GS) allows interrogation of the full spectrum of inborn genetic variation in an individual and RNA profiling provides a snapshot of the cardiac-specific pathogenic effects on gene expression.
Identify candidate genetic modifiers of hypertrophic cardiomyopathy phenotype.
We performed GS of 48 individuals with variants in
, the gene encoding beta myosin heavy chain, and a personal or family history of cardiomyopathy. The genome sequences were annotated with a custom pipeline optimized for cardiovascular gene variant detection. We utilized multiple lines of evidence to prioritize genes together with rare variant gene-based association testing to identify candidate genetic modifiers.
GS identified the
variant in all 48 cases. Several variants were reclassified based on best available data. We identified known disease-associated genes (
),
candidate modifiers (
,
and novel candidate modifiers of cardiomyopathy including
and
. We identified regulatory variants and intergenic regions associated with the phenotypes. Using RNA profiling, we show that several genes identified through gene-based association testing are differentially regulated in human hypertrophic cardiomyopathy, and in models of disease.
Evaluation of the whole genome, even in the case of alleged monogenic disease, leads to important new insights. The identified variants, regions, and genes are candidates to modify disease presentation in cardiomyopathy.
Publisher
Frontiers Media SA,Frontiers Media S.A
